The first Sanofi trade was made in Q1 2015. Since then Paul Tudor Jones II bought shares two more times and sold shares on two occasions. The investor sold all their shares in Q2 2016 and doesn't own any shares in Sanofi anymore.
NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A ALTUVIII...
IIFL downgraded Sanofi India to Reduce from ADD earlier with a target price of Rs 8,125. The stock continues to underperform domestic market growth. New laun...
Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A ALTUVIIIO is a first-in-class, high-sustained factor VIII rep...
ALTUVIIIOTM late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing XTEND-Kids...